HS2.DE Henry Schein (XETRA) €74.06 pre-market 18 Mar 2026: oversold bounce setup vs 50-day avg

In pre-market trading on XETRA we see HS2.DE stock at €74.06, a hair above the 50-day average of €71.52 and well above the 200-day average of €66.59. This price position frames a classic oversold-bounce opportunity for short-term traders in Germany. Henry Schein, Inc. (HS2.DE) posts a trailing EPS of 3.23 and a PE of 22.93. We use Meyka AI data and sector context to explain catalysts, valuation, and a practical bounce trade plan for the healthcare distribution and services company.

HS2.DE stock pre-market snapshot

HS2.DE stock opened at €74.04 and is quoted €74.06 pre-market on XETRA for 18 Mar 2026. The previous close was €73.98 and the day range shows €74.04–€74.06. Market cap stands near €9.38B and shares outstanding are 126,708,000. Key trailing metrics include EPS 3.23 and PE 22.93. Year high is €78.96 and year low is €58.62, which frames recent volatility and the scope for a short-term rebound.

HS2.DE stock technicals and oversold bounce setup

Price sits just above the 50-day average (€71.52) and well above the 200-day average (€66.59), which supports a mean-reversion bounce thesis. Average volume on XETRA is very low at 15.00 shares, indicating liquidity risk for large orders. The limited on-exchange volume raises execution and slippage risk, so smaller position sizes are prudent. Technical momentum indicators in our feed are incomplete, so we rely on moving averages and price action for the oversold-bounce signal.

HS2.DE stock fundamentals and valuation

Henry Schein operates in Healthcare distribution and technology services with revenue per share of 107.47 and free cash flow per share of 3.25. Price-to-sales is 0.84 and price-to-book is 3.06. Debt-to-equity is 1.02, and interest coverage is 5.27, showing manageable but material leverage. Return on equity is 11.58%, and net profit margin is 3.02%. These metrics support a defensive growth profile inside the Healthcare sector while highlighting margin sensitivity.

Meyka AI rates HS2.DE with a score out of 100

Meyka AI rates HS2.DE with a score of 72.54 out of 100 and assigns a B+ (BUY) suggestion. This grade factors in S&P 500 comparison, sector and industry performance, financial growth, key metrics, forecasts, and analyst consensus. The grade highlights above-average fundamentals and growth potential versus peers, but it is not guaranteed and is not financial advice.

HS2.DE stock forecast and price-targets

Meyka AI’s forecast model projects a 1-year price of €73.29, a 3-year price of €78.57, and a 5-year price of €83.85. Versus the current €74.06 that implies a short-term downside of -1.04%, a 3-year upside of +6.09%, and a 5-year upside of +13.23%. For trading we set a conservative bounce target at €78.00, a bullish target at €87.00, and a downside guard at €68.00. Forecasts are model-based projections and not guarantees.

HS2.DE stock catalysts, risks and sector context

Healthcare sector valuation averages show a PE around 29.52, higher than Henry Schein’s 22.93, suggesting relative value. Catalysts include better demand in dental and small-practice markets and pickup in value-added software services. Key risks are leverage (net debt to EBITDA near 3.50), thin XETRA liquidity, and margin pressure from distribution costs. For competitor context see market comparisons on Investing.com and related reports. source source.

Final Thoughts

HS2.DE stock trades at €74.06 pre-market on XETRA on 18 Mar 2026, with mixed signals for an oversold bounce. Technical setup shows price above the 50-day average (€71.52) and 200-day average (€66.59), which supports a measured mean-reversion trade. Fundamentals show solid free cash flow per share (3.25) and a PE of 22.93, cheaper than the Healthcare average PE 29.52. Meyka AI’s forecast model projects €73.29 for one year and €83.85 at five years, implying modest short-term downside and multi-year upside of +13.23% versus today. For a disciplined oversold-bounce approach we suggest a staggered entry, a tight stop near €68.00, and profit targets at €78.00 and €87.00. Remember these are model-driven forecasts from Meyka AI and not guarantees. Size positions to XETRA liquidity and your risk plan.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.